Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iuliano, R.
Right arrow Articles by Fusco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iuliano, R.
Right arrow Articles by Fusco, A.
[Cancer Research 63, 882-886, February 15, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

An Adenovirus Carrying the Rat Protein Tyrosine Phosphatase {eta} Suppresses the Growth of Human Thyroid Carcinoma Cell Lines in Vitro and in Vivo1

Rodolfo Iuliano, Francesco Trapasso, Ilaria Le Pera, Filippo Schepis, Irene Samà, Alessandra Clodomiro, Kristoffel R. Dumon, Massimo Santoro, Lorenzo Chiariotti, Giuseppe Viglietto and Alfredo Fusco2

Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia di Catanzaro, Università degli Studi di Catanzaro "Magna Graecia," 88100 Catanzaro, Italy [R. I., F. T., I. L. P., F. S., I. S., A. C., L. C., A. F.]; Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107 [K. R. D.]; and Centro di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II," 80131 Napoli, Italy [M. S., G. V., A. F.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We demonstrated previously that rat tyrosine phosphatase r-PTP{eta} expression was suppressed in rat and human thyroid neoplastic cells, and that restoration of r-PTP{eta} expression reverted the malignant phenotype. To investigate the potential of this gene for cancer therapy, we generated an adenovirus carrying the r-PTP{eta} cDNA (Ad-r-PTP{eta}). This virus infected human thyroid carcinoma cells and overexpressed the r-PTP{eta} protein. Overexpression of r-PTP{eta} significantly inhibited the growth of four thyroid carcinoma cell lines. Cell growth inhibition was associated with down-regulation of extracellular signal-regulated kinase 1/2 activity, with increased levels of the cell-cycle inhibitor p27kip1 protein and with dephosphorylation of PLC{gamma}1, a substrate of DEP-1, the human homologue of r-PTP{eta}. Finally, the growth of xenograft tumors induced in athymic mice by anaplastic thyroid carcinoma ARO cells transduced with the Ad-r-PTP{eta} virus was drastically reduced. These data suggest that gene therapy based on restoration of PTP{eta} function has potential in the treatment of human thyroid malignant neoplasias.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Thyroid tumors include a wide spectrum of lesions that differ in phenotypic characteristics and biological behavior: benign adenomas, differentiated carcinomas and undifferentiated ATCs3 (1) . Treatment with radioactive iodide is very effective in cases of differentiated carcinomas. Conversely, undifferentiated carcinomas are refractory to chemo- and radiotherapy, and are among the most lethal human neoplasms (2) . Therefore, ATCs are an appropriate target for novel therapeutic approaches.

The vector-mediated transduction of genes able to arrest tumor growth rate, defined as "cancer gene therapy," may be a useful alternative or complementary strategy to conventional therapies. Gene therapy has been successful in experimental models of thyroid carcinoma. In fact, suppression of the HMGA1 proteins leads to the apoptotic death of two human thyroid carcinoma cell lines (3) . Similarly, transduction of adenovirus-mediated p53 inhibited thyroid carcinoma cell growth (4) . We recently showed that an E1B Mr 55,000 gene-defective adenovirus (ONYX-015), which replicates only in cells with impaired p53 function, killed thyroid carcinoma cells. Furthermore, the ONYX-015 virus and two antineoplastic drugs (doxorubicin and paclitaxel) acted synergistically (5) .

These results prompted us to investigate the potential of the r-PTP{eta} gene for cancer therapy. This gene, isolated by our group, encodes a receptor-type tyrosine phosphatase protein of which the expression is reduced drastically in rat thyroid cells transformed by acute murine retroviruses (6) . In addition, the expression of HPTP{eta}/DEP-1, the human homologue of r-PTP{eta}, is down-regulated in human thyroid carcinomas (7) . The re-expression of the r-PTP{eta} gene in highly malignant rat thyroid cells transformed by retroviruses carrying the v-mos and v-ras-Ki oncogenes suppresses their malignant phenotype. The level of the cyclin-dependent kinase inhibitor p27Kip1 protein was increased in the r-PTP{eta}-transfected cells because of the decreased proteasome-dependent degradation rate. Because suppression of p27Kip1 protein synthesis blocked the inhibition of growth induced by r-PTP{eta}, we proposed that r-PTP{eta} tumor-suppressor activity is mediated by p27Kip1 protein stabilization, which, in turn, depends on the r-PTP{eta}-mediated inhibition of ERK1/2 activation induced by the v-ras-Ki and v-mos oncogenes (7) . The mouse homologue of r-PTP{eta}/DEP-1 (ptprj) has been implicated recently in susceptibility to mouse colon cancer (8) . Allelic imbalance in loss of heterozygosity and missense mutations of this gene are frequent in human colon, lung, and breast cancers (8) .

The aim of our study was to generate an adenovirus carrying the full-length r-PTP{eta} cDNA (Ad-r-PTP{eta}) to examine whether r-PTP{eta}/DEP-1 overexpression could be effective in treating human thyroid carcinomas. We found that the Ad-r-PTP{eta} virus inhibited thyroid carcinoma cell growth, and that growth inhibition was associated with an increased p27Kip1 protein level and reduced ERK1/2 activity. Moreover, r-PTP{eta} overexpression reduced the phosphorylation level of PLC{gamma}1, a substrate of DEP-1 (9) . Finally, the growth of xenograft tumors induced in athymic mice by the injection of ARO cells was drastically reduced by Ad-r-PTP{eta} treatment.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
The BC-PAP, NIM, NPA, and TPC-1 cells were derived from human thyroid papillary carcinomas. WRO were derived from human thyroid follicular carcinoma. ARO and FB-1 were derived from human anaplastic carcinomas (10 , 11) . All of the cell lines were grown in DMEM supplemented with 10% fetal bovine serum and ampicillin/streptomycin antibiotics at 37°C and 5% CO2.

Western Blotting and Immunoprecipitation.
Cells were washed once in cold PBS and lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 1% (v/v) NP40, 150 mM NaCl, complete protease inhibitors (Roche), 50 mM NaF, and 1 mM sodium vanadate. Lysates were clarified by centrifugation at 10,000 x g for 15 min, and the supernatant was collected. Protein concentration was determined by a modified Bradford assay (Bio-Rad). Five-hundred µg of proteins were immunoprecipitated by using 1 µg of anti-PLC{gamma}1 antibodies and 20 µl of protein G-agarose (Upstate Biotechnology). Immunoprecipitates were washed three times in lysis buffer. Total proteins or immunoprecipitates were separated on 4–20% polyacrylamide gels and transferred to polyvinylidene difluoride filter membranes (Immobilon-P; Millipore). Membranes were blocked in 5% nonfat dry milk (1% BSA for phosphotyrosine detection), incubated with primary antibodies, detected by the appropriate secondary antibodies, and revealed with an enhanced chemiluminescence system (Santa Cruz Biotechnology). The primary antibodies used were: polyclonal rabbit antibodies generated against the intracellular region of r-PTP{eta} fused to GST (7) ; anti-pERK, anti-ERK, anti-p27, anti-PLC{gamma}1, and anti-{gamma}-tubulin from Santa Cruz Biotechnology; and antiphosphotyrosine from Transduction Laboratories.

Preparation of Recombinant Adenovirus and Infection Protocol.
The r-PTP{eta} insert was prepared by digesting the cDNA with PauI and EcoRI at the 5' and 3' end, respectively. Blunt ends were generated with Klenow DNA polymerase, and the cDNA fragment was cloned into the transfer vector pQBI/AdCMV5-GFP (Qbiogene) linearized previously with BglII and then treated with Klenow to generate compatible blunt ends.

The pQBI/AdCMV5-GFP/r-PTP{eta} construct was cotransfected with the E1/E3 deleted Ad5 backbone viral DNA. Viral plaques were screened for the presence of the r-PTP{eta} protein by Western blot with specific r-PTP{eta} antibodies. One positive clone was plaque-purified and amplified on 293 cells. After freeze/thaw cycles, the adenoviruses in the supernatant were purified on two successive cesium chloride gradients. The recombinant adenovirus was titered by the TCID50 method and aliquoted. Virus stocks were stored at -80°C. An adenovirus carrying GFP under the control of a CMV promoter (Ad5.CMV-GFP; Qbiogene) was used as a control.

Cells (5 x 104) were seeded in a six-well plate. After 24 h, cells were infected at a MOI of 100 with Ad-r-PTP{eta} or Ad-GFP for 90 min using 500 µl of infection medium (DMEM + 2% fetal bovine serum) at 37°C in a 5% CO2 incubator. The optimal MOI for each cell line was determined in pilot experiments with Ad-GFP. At an MOI of 100, the cell lines used became GFP-positive without manifesting signs of toxicity. Infected cells were harvested and counted daily using a hematocytometric chamber. Three independent experiments were performed for each cell line.

The percentage of cell growth inhibition was calculated with the formula: (x - y)/x (x is the difference between the mean cell count 4 days after Ad-GFP infection and the number of cells plated; y is the difference between the mean cell count 4 days after Ad-r-PTP{eta} infection and the number of cells plated).

Tumorigenicity Assay.
ARO cells (1 x 106) uninfected or infected at an MOI of 100 with Ad-r-PTP{eta} or Ad-GFP were injected s.c. into athymic mice. Tumor volumes and weights were evaluated 30 days later, after which the mice were killed. Tumor volumes (V) were calculated by the rotational ellipsoid formula: V = A x B2/2 (A = axial diameter; B = rotational diameter). None of the mice showed signs of wasting or other signs of toxicity.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
HPTP{eta}/DEP-1 Expression in Thyroid Cell Lines.
Expression of DEP-1 was examined in seven cell lines derived from ATCs (ARO and FB-1), from a thyroid carcinoma with a follicular histotype (WRO), and from thyroid carcinomas with a papillary histotype (BC-PAP, NIM, NPA, and TPC-1). Because DEP-1 expression is regulated by cell density (12) , DEP-1 protein levels being higher in dense than in sparse cultures, we evaluated DEP-1 protein levels by Western blot using protein extracts from cells at 50% confluency and at full confluency. As shown in Fig. 1Citation , two protein bands were detected, which probably represent differently glycosylated DEP-1 forms, as observed by others (12) . DEP-1 protein levels were lower in all of the thyroid carcinoma cell lines than in thyroid gland. In particular, DEP-1 expression was very low in BC-PAP and ARO cells. Moreover, in some cell lines (ARO, NIM, and WRO), DEP-1 expression was not influenced by cell density, whereas in other cell lines (BC-PAP, FB-1, NPA, and TPC-1) DEP-1 protein levels significantly increased when the cells reached full confluency. The differences in DEP-1 expression consequent to changes in cell density in the thyroid carcinoma cells did not depend on the absolute protein levels in the various cell lines.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. DEP-1 expression in various human thyroid carcinoma cell lines. Total proteins were extracted from cells at 50% confluency and at full confluency. Fifty µg of total proteins were separated and blotted as described under "Materials and Methods," and anti-r-PTP{eta} specific antibodies were used to detect DEP-1. The protein levels of {gamma}-tubulin were detected with specific antibodies and used as a control of equal loading.

 
Transduction of r-PTP{eta} Gene Inhibits Thyroid Carcinoma Cell Growth.
To evaluate the therapeutic potential of r-PTP{eta} as a therapeutic gene, we generated a replication defective adenovirus carrying r-PTP{eta} cDNA (Ad-r-PTP{eta}). The cDNA was cloned into the transfer vector pQBI AdCMV5-GFP under the transcriptional control of a CMV promoter. This vector also carries the GFP reporter gene of which the expression is controlled by another independent CMV promoter (Fig. 2A)Citation . The recombinant adenovirus was then obtained as described under "Materials and Methods." The thyroid cell lines ARO, FB-1, NIM, and TPC-1 were infected with the Ad-r-PTP{eta} virus at an MOI of 100. Significant r-PTP{eta} protein levels were detected by Western blot analysis in all of the cell lysates collected at different time points after Ad-r-PTP{eta} infection. r-PTP{eta} was overexpressed both in FB-1 cells that express significant protein levels of endogenous DEP-1 and in ARO cells that express very low DEP-1 protein levels (Fig. 2B)Citation . Protein r-PTP{eta} was not overexpressed in the same carcinoma cells infected with the control virus (Ad-GFP). As expected, the protein band of r-PTP{eta} has a molecular weight lower than that of endogenous DEP-1 (6) .



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Schematic representation of the vector used to generate the recombinant adenovirus transducing r-PTP{eta} gene (A). r-PTP{eta} expression in thyroid cells infected with Ad-r-PTP{eta} at MOI = 100. Cells were lysed at the postinfection time points indicated. Thirty µg of total proteins were separated and blotted. Immunodetection was performed with anti-r-PTP{eta} specific antibodies. The protein levels of {gamma}-tubulin were detected with specific antibodies and used as a control of equal loading (B).

 
Subsequently, we evaluated the growth rate of four thyroid carcinoma cells infected with Ad-r-PTP{eta} and control adenovirus (Ad-GFP). As shown in Fig. 3Citation , the cell growth rate was reduced significantly in ARO, FB-1, NIM, and TPC-1 cell lines infected with Ad-r-PTP{eta} compared with the same cells infected with the control virus. The percentage of growth inhibition, calculated as described under "Materials and Methods," 4 days after infection was 85% in ARO cells, 73% in FB-1 cells, 62% in NIM cells, and 77% in TPC-1 cells.



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Inhibitory effects of Ad-r-PTP{eta} infection on the growth of human thyroid cell lines. The cells indicated were infected with Ad-r-PTP{eta} or Ad-GFP (control adenovirus) at MOI = 100 and counted daily. Representative curves of three independent experiments are reported.

 
Mechanisms of r-PTP{eta} Action.
Because we demonstrated that r-PTP{eta} inhibits the growth of malignant rat thyroid cell lines by down-regulating ERK1/2 activity and by up-regulating p27kip1 (7) , we evaluated phosphorylated ERK1/2 and p27kip1 protein levels in human thyroid cell lines infected with Ad-r-PTP{eta}. As shown in Fig. 4ACitation , Western blot analysis demonstrated a decrease of phosphorylated ERK1/2 and an increase of p27kip1 protein levels in Ad-r-PTP{eta}-infected cells compared with cells infected with the control adenovirus.



View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Decreased ERK1/2 activity and increased p27 protein levels are associated with r-PTP{eta} overexpression. The cells indicated were infected with Ad-r-PTP{eta} or Ad-GFP at MOI = 100 and lysed 3 days later. Thirty µg of total proteins were separated and blotted. Immunodetection was performed by using anti-r-PTP{eta}, anti-pERK, anti-ERK, anti-p27, and anti-{gamma}-tubulin specific antibodies (A). Immunoprecipitation of PLC{gamma}1 in ARO cell lysates infected with Ad-r-PTP{eta} or Ad-GFP (control adenovirus). Five-hundred µg of total proteins were immunoprecipitated with anti-PLC{gamma}1-specific antibodies. The immunoprecipitated proteins were separated, blotted, and detected with antiphosphotyrosine or anti-PLC{gamma}1 antibodies (B).

 
To verify whether r-PTP{eta} acts on the same substrates as its human homologue DEP-1 in human thyroid cell lines, we evaluated r-PTP{eta} activity on PLC{gamma}1, a DEP-1 substrate (9) . We immunoprecipitated protein extracts of the infected ARO cells with specific antibodies that recognize human PLC{gamma}1, and then we detected the immunoprecipitates with antiphosphotyrosine antibodies. As shown in Fig. 4BCitation , tyrosine phosphorylated PLC{gamma}1 was detectable in Ad-GFP-infected ARO cells but not in the ARO cells infected with the Ad-r-PTP{eta} virus. This result demonstrates that r-PTP{eta} is able to dephosphorylate DEP-1 substrates.

Ad-r-PTP{eta} Inhibits Tumor Growth in Mice.
Finally, to evaluate the efficacy of Ad-r-PTP{eta} in inhibiting tumor growth in vivo, we examined the effect of Ad-r-PTP{eta} in ARO cells that generate tumors when injected s.c. into athymic mice. ARO cells uninfected or infected with either Ad-r-PTP{eta} or Ad-GFP at an MOI of 100 were inoculated into 24 mice (8 mice per group). Thirty days later, the average tumor size in mice injected with Ad-r-PTP{eta}-infected cells was ~8-fold smaller than those in the mice injected with uninfected cells or Ad-GFP-infected cells (Fig. 5)Citation .



View larger version (41K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Tumor growth inhibition after Ad-r-PTP{eta} infection. ARO cells (1 x 106) infected at MOI = 100 or uninfected were injected s.c. into the flanks of nude mice. There 8 eight animals per group. The animals were killed 30 days after the cell injection, and the tumor size and weight were measured. Tumor weights are expressed in grams (A) and tumor sizes are expressed in mm3 (B); bars, ±SD.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
This study shows that restoration and/or overexpression of the r-PTP{eta} gene in thyroid carcinoma may represent a novel treatment approach to human thyroid carcinomas. The undifferentiated anaplastic carcinoma could be a particularly appropriate target for innovative gene therapy, being a very aggressive human neoplasia that is resistant to any known therapeutic approach (2) .

We found that infection of thyroid cells with a recombinant adenovirus carrying the full-length cDNA of r-PTP{eta} (Ad-r-PTP{eta}) resulted in the synthesis of a relevant amount of r-PTP{eta} protein, and that r-PTP{eta} gene overexpression inhibited the growth of all of the thyroid carcinoma cell lines tested. The inhibitory effect of Ad-r-PTP{eta} was strongest in ARO cells, which express very low levels of endogenous DEP-1 protein, and lowest in NIM cells, in which endogenous DEP-1 protein levels are unaffected by cell confluency. Therefore, it can be speculated that cells in which DEP-1 expression increases with cell density could be more sensitive to the inhibitory effect of r-PTP{eta}. Furthermore, the transduction of r-PTP{eta} in malignant human thyroid cells resulted in inhibition of tumor growth in athymic mice.

We show that cell growth inhibition correlates with decreased ERK1/2 activity and increased p27kip1 protein levels. These results are consistent with our previous data on rat thyroid malignant cells (7) and with the critical role played by p27kip1 in inhibiting the growth of human thyroid cell lines (13) . Furthermore, r-PTP{eta} overexpression induces the tyrosine dephosphorylation of PLC{gamma}1, a DEP-1 substrate (8) . PLC{gamma}1, when activated by tyrosine phosphorylation, increases the growth and invasiveness of various cancer cell types (14 , 15) . As a consequence, PLC{gamma}1 dephosphorylation by r-PTP{eta} may inhibit PLC{gamma}1 activity. This in turn suggests that Ad-r-PTP{eta} might be viable for the treatment of tumors with elevated PLC{gamma}1 activity. Data on cell growth inhibition consequent to DEP-1 and r-PTP{eta} overexpression in breast (16) and pancreatic4 carcinoma cell lines, suggest that Ad-r-PTP{eta} may be useful for cancers other than thyroid carcinomas. Support for this concept comes from recent findings showing that DEP-1 is deleted frequently in human colon, lung, and breast cancers (8) .

Given the finding that r-PTP{eta} re-expression is associated with partial restoration of differentiated thyroid functions (7) , one may envisage r-PTP{eta}-based gene therapy combined with radioactive iodine treatment in cases of ATC. In fact, being undifferentiated, these tumors cannot trap iodide and are therefore resistant to iodine treatment. In these optics, the differentiation state of Ad-r-PTP{eta}-infected human cell lines deserves further study. The possibility of synergism between the Ad-r-PTP{eta} virus and conventional antineoplastic drugs should also be investigated.

In conclusion, restoration of normal r-PTP{eta} activity in human thyroid carcinoma cells may represent a novel therapeutic approach to thyroid cancer therapy.


   ACKNOWLEDGMENTS
 
We thank the Associazione Partenopea per la Ricerche Oncologiche (APRO) for its support. We also thank Jean Ann Gilder for editing the text.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants from Associazione Italiana Ricerca sul Cancro (Progetto Speciale Oncosoppressori), the "Progetto Finalizzato Biotecnologie" of the Consiglio Nazionale delle Ricerche, the Ministero dell’Universitàe della Ricerca Scientifica e Tecnologica (MURST) projects "Terapie antineoplastiche innovative" PRIN and "Piani di Potenziamento della Rete Scientifica e Tecnologica" CLUSTER C-04, and the "Ministero della Sanità" and "Fondazione Pascale." Back

2 To whom requests for reprints should be addressed, at Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II," via Pansini 5, 80131 Napoli, Italy. Phone: 39-081-7463056; Fax: 39-081-7463037; E-mail: afusco{at}napoli.com Back

3 The abbreviations used are: ATC, anaplastic thyroid carcinoma; GFP, green fluorescent protein; MOI, multiplicity of infection; ERK, extracellular signal-regulated kinase; CMV, cytomegalovirus. Back

4 F. Trapasso and A. Fusco, unpublished observations. Back

Received 8/12/02. Accepted 12/13/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hedinger C., Williams E. D., Sobin L. H. The WHO histological classification of thyroid tumors: a commentary on the Ed. 2. Cancer (Phila.), 63: 908-911, 1989.[Medline]
  2. Sherman S. I., Brierley J. D., Sperling M., Ain K. B., Bigos S. T., Cooper D. S., Haugen B. R., Ho M., Klein I., Ladenson P. W., Robbins J., Ross D. S., Specker B., Taylor T., Maxon H. R., III Prospective multicenter study of treatment of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer (Phila.), 83: 1012-1021, 1998.[Medline]
  3. Scala S., Portella G., Fedele M., Chiappetta G., Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. USA, 97: 4256-4261, 2000.[Abstract/Free Full Text]
  4. Nagayama Y., Yokoi H., Takeda K., Hasegawa M., Nishihara E., Namba H., Yamashita S., Niwa M. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab., 85: 4081-4086, 2000.[Abstract/Free Full Text]
  5. Portella G., Scala S., Vitagliano D., Vecchio G., Fusco A. ONYX-015, an E1B gene-defective adenovirus. Induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab., 87: 2525-2531, 2002.[Abstract/Free Full Text]
  6. Zhang L., Martelli M. L., Battaglia C., Trapasso F., Tramontano D., Viglietto G., Porcellini A., Santoro M., Fusco A. Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. Exp. Cell Res., 235: 62-70, 1997.[Medline]
  7. Trapasso F., Iuliano R., Boccia A., Stella A., Visconti R., Bruni P., Baldassarre G., Santoro M., Viglietto G., Fusco A. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol. Cell. Biol., 20: 9236-9246, 2000.[Abstract/Free Full Text]
  8. Ruivenkamp C. A., van Wezel T., Zanon C., Stassen A. P., Vlcek C., Csikos T., Klous A. M., Tripodis N., Perrakis A., Boerrigter L., Groot P. C., Lindeman J., Mooi W. J., Meijjer G. A., Scholten G., Dauwerse H., Paces V., van Zandwijk N., van Ommen G. J., Demant P. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet., 31: 295-300, 2002.[Medline]
  9. Baker J. E., Majeti R., Tangye S. G., Weiss A. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase C{gamma}1 phosphorylation. Mol. Cell. Biol., 21: 2393-2403, 2001.[Abstract/Free Full Text]
  10. Cerutti J., Trapasso F., Battaglia C., Zhang L., Martelli M. L., Berlingieri M. T., Fagin J., Santoro M., Fusco A. Blockage of c-MYC protein synthesis in human thyroid carcinoma cell lines reduces their growth in soft agar. Clin. Cancer Res., 2: 119-126, 1996.[Abstract/Free Full Text]
  11. Fiore L., Polline L. E., Fontanini G., Casalone R., Berlingieri M. T., Giannini R., Pacini F., Miccoli P., Toniolo A., Fusco A., Basolo F. Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J. Clin. Endocrinol. Metab., 82: 4094-4100, 1997.[Abstract/Free Full Text]
  12. Ostman A., Yang Q., Tonks N. K. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc. Natl. Acad. Sci. USA, 91: 9680-9684, 1994.[Abstract/Free Full Text]
  13. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., Barone M. V., Chiappetta G., Vento M. T., Spiezia S., Fusco A., Viglietto G. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Investig., 104: 865-874, 1999.[Medline]
  14. Carpenter G., Ji Q. Phospholipase C-{gamma} as a signal-transducing element. Exp. Cell Res., 253: 15-24, 1999.[Medline]
  15. Kassis J., Moellinger J., Lo H., Greenberg N. M., Kim H. G., Wells A. A role for phospholipase C-{gamma}-mediated signaling in tumor cell invasion. Clin. Cancer Res., 5: 2251-2260, 1999.[Abstract/Free Full Text]
  16. Keane M. M., Lowrey G. A., Ettenberg S. A., Dayton M. A., Lipkowitz S. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res., 56: 4236-4243, 1996.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. L. Sallee and K. Burridge
Density-enhanced Phosphatase 1 Regulates Phosphorylation of Tight Junction Proteins and Enhances Barrier Function of Epithelial Cells
J. Biol. Chem., May 29, 2009; 284(22): 14997 - 15006.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
R. Iuliano, C. Raso, A. Quintiero, I. L. Pera, F. Pichiorri, T. Palumbo, D. Palmieri, A. Pattarozzi, T. Florio, G. Viglietto, et al.
The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization
J. Biochem., March 1, 2009; 145(3): 377 - 385.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio
Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2
Endocrinology, September 1, 2008; 149(9): 4736 - 4746.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
K. A. B. Knostman, S. M. Jhiang, and C. C. Capen
Genetic Alterations in Thyroid Cancer: The Role of Mouse Models
Vet. Pathol., January 1, 2007; 44(1): 1 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Arena, A. Pattarozzi, A. Massa, J.-P. Esteve, R. Iuliano, A. Fusco, C. Susini, and T. Florio
An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase {eta}
Mol. Endocrinol., January 1, 2007; 21(1): 229 - 246.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Takahashi, K. Takahashi, R. L. Mernaugh, N. Tsuboi, H. Liu, and T. O. Daniel
A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis
Blood, August 15, 2006; 108(4): 1234 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Iervolino, R. Iuliano, F. Trapasso, G. Viglietto, R. M. Melillo, F. Carlomagno, M. Santoro, and A. Fusco
The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins.
Cancer Res., June 15, 2006; 66(12): 6280 - 6287.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Trapasso, S. Yendamuri, K. R. Dumon, R. Iuliano, R. Cesari, B. Feig, R. Seto, L. Infante, H. Ishii, A. Vecchione, et al.
Restoration of receptor-type protein tyrosine phosphatase {eta} function inhibits human pancreatic carcinoma cell growth in vitro and in vivo
Carcinogenesis, November 1, 2004; 25(11): 2107 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Massa, F. Barbieri, C. Aiello, S. Arena, A. Pattarozzi, P. Pirani, A. Corsaro, R. Iuliano, A. Fusco, G. Zona, et al.
The Expression of the Phosphotyrosine Phosphatase DEP-1/PTP{eta} Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation
J. Biol. Chem., July 9, 2004; 279(28): 29004 - 29012.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iuliano, R.
Right arrow Articles by Fusco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iuliano, R.
Right arrow Articles by Fusco, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online